

VOLUME 70, 2001 KEYWORD INDEX

- α_2 -Adrenoceptor antagonist, 141
 α_7 Receptors, 447
 α_7 Subunit, 561, 571
Acepromazine, 341
Acetylcholine release, 227
Acetylcholine, 279, 439, 457, 531
Acetylcholinesterase activity, 227
Acute dependence, 193
Acute functional tolerance, 167
Acute tolerance, 387
Addiction, 515
Adenosine, 279
Adolescent rats, 475
Adrenergic antagonists, 341
Adsorption, 375
Adult rats, 475
Alcohol, 243
Allosteric modulation, 55
Alpha-flupenthixol, 193
Alpha-7, 467
AMPA, 421
Amphetamine, 65, 181, 311, 317, 367, 381
Animal communication, 317
ANOVA, analysis of variance, 23
Antagonist, 193
Anterior hypothalamic–preoptic area, 317
Anticonvulsants, 157
Anticonvulsive effect, 375
Antidepressants, 187
Antidepressant treatment, 15
Antiemetic agents, 267
Anxiety, 1, 123, 411, 491
Anxiolytic, 133
Apomorphine, 219
AST-120, 375
Axotomy, 457
- β -Alanine, 333
Behavior, 157
Behavioral sensitization, 55
Benzodiazepine, 133
Bipolar disorder, 561
- Blood brain barrier, 209
Blood concentration, 375
Blood ethanol levels, 333
Body weight, 475
Brain damage, 341
Brainstem, 457
Burying behaviour, 85
Buspirone, 85
- Cannabinoids, 123
Center time, 475
Central nervous system, 251
Cerebellum, 199, 447
Cerebral cortex, 227
Chick, 251
Chlordiazepoxide, 133
Choice, 257
Chronic nicotine, 497
Chronic stress, 209
Cigarettes, 439
Cl uptake, 55
COC-25, cocaine HCl-injected group at 25 mg/kg, 23
COC-50, cocaine HCl-injected group at 50 mg/kg, 23
Cocaine, 55, 65, 257, 381
Compensatory response, 43
Conditioned avoidance, 279
Conditioned drug response, 515
Conditioned place aversion, 531
Conditioning, 193
Core temperature, 341
Corticosterone, 209, 305
Cortisol, 243
Cross-generalization, 31
Cyclosporine, 267
- D₁ agonist, 257
D₂ agonist, 257
D₁:D₂ agonist mixtures, 257
D₃ antagonist, 43
DA, dopamine, 23
D-Amphetamine, 397
Dehydroepiandrosterone sulfate, 243
- Delusional misidentification, 571
Dementia with Lewy bodies, 571
Depression, 15, 65, 531
Designer drugs, 311
Desipramine, 65
Developmental, 387
Diazepam, 85, 411
Di-hydro- β -erythroidine hydrobromide, 491
DMSA, 199
Dog, 141
DOPAC, 199
Dopamine, 123, 181, 193, 199, 219, 279, 317, 439, 497, 531
Dopamine antagonists, 341
Dopamine (DA), 157
Dorsal raphé nucleus, 491
Dose–response, 387
Drug-cues, 515
Drug discrimination, 31, 381
Drug preference, 257
Drug reinforcement, 515
Drug withdrawal, 531
- ECS, 15
Ejaculation, 141
Electrolytes, 243
Elevated plus maze, 85
Emotional behavior, 291
Epilepsy, 421
Ethanol sensitivity, 387
Ethanol, 31, 167, 227, 333
Eticlopride, 181
Exploratory behaviour, 123
8-OH-DPAT, 95
- Fasting, 243
Feeding, 475
Five-choice serial reaction time task (5-CSRTT), 505
Fixed ratio, 31
Fluoxetine, 65
Food deprivation, 341
Food intake, 251

- Forced swim test, 187
 Fusaric (5-butylpicolinic) acid, 251
 5-HT, 1
 5-HT, serotonin, 23
 50-kHz calls, 317

 GABA, 31, 123
 GABA-A receptor, 115
 Gamma-hydroxybutyrate (GHB), 31
 Gastric ulcers, 1
 GBR 12909, 23
 GBR-25, GBR 12909-injected group
 at 25 mg/kg, 23
 GBR-50, GBR 12909-injected group
 at 50 mg/kg, 23
 Genetic linkage, 561
 Genetics, 219
 Glu release, 447
 Glucagon-like peptide-1 (GLP-1),
 251
 Glutamate, 317, 531
 Granule cells, 447
 Gulf War Illness, 209

 Hallucinogens, 311
 Haloperidol, 317
 HAS, 387
 Hippocampus, 227, 291, 467
 Histamine, 427
 Holeboard, 123
 Homovanillic acid, 199
 Horizontal activity, 475
 Hypophagia, 367
 Hypotaurine, 333
 Hypothalamic–pituitary–adrenal
 axis, 243
 Hypothalamus, 123, 457
 Hypothermia, 167

 Imipramine, 187
 Incoordination, 167
 Instrumental learning model, 367
 Intracerebroventricular infusion, 353
 Intracranial self-stimulation, 531

 Kaolin intake, 267
 Kindling, 291

 Lactating and ovariectomized rats, 85
 LAS, 387
 Lateral perforant path, 353
 Lead, 199
 Limbic seizures, 341
 Locomotion, 23, 475
 Locomotor activity, 273, 333, 491,
 505

 Long–Evans hooded rats, 31
 Long-term potentiation, 237, 353
 Low-level inhalation exposure, 175
 LY451646, 187
 Lysophosphatidylcholine, 105

 Males and females, 475
 Maternal separation, 397
 MDMA, 311
 Medial preoptico-anterior hypothala-
 mic area, 115
 Median raphe nucleus, 1
 Medulla, 199
 Melatonin, 325
 Memory, 77, 467
 Mental illness, 561
 Metabolites, 411
 Methamphetamine, 273
 Methylation, 105
 Mixture, 31
 MLA, 467
 Morphine, 353, 359
 Morphine dependence, 149
 Morphology, 291
 Motoneurons, 457
 Motor activity, 123, 497
 MPP⁺, 105
 MPTP, 105

 Naloxone, 359
 Naloxone-precipitated withdrawal,
 149
 Nausea, 267
 NE, norepinephrine, 23
 Neuroleptic, 193, 561
 Neuronal cell loss, 291
 Neurotoxicity, 157
 Nicotine, 475, 491, 505, 515, 531
 Nicotine abstinence syndrome, 551
 Nicotine addiction, 561
 Nicotine binding, 561
 Nicotine dependence, 551
 Nicotine withdrawal, 551
 Nicotinic, 467
 Nicotinic acetylcholine receptors,
 561, 571
 Nicotinic ACh receptors, 447
 Nicotinic antagonists, 457, 551
 Nicotinic receptor, 439
 Noradrenergic system, 251
 Nucleus accumbens, 497

 Obsessive–compulsive disorder, 95
 Ontogeny, 273, 387
 Open field, 227, 333, 411
 Open-field test, 95

 Opiate withdrawal, 193
 Opioid, 531
 Opioid blockade, 77
 Opioids, 359
 Optic tectum, 199
 Oxidative stress, 325

 Parkinson's disease, 105
 Patch clamp, 447
 Pavlovian conditioning, 279
 Pelvic thrusting behavior, 141
 Penile erection, 141
 Pentylentetrazol kindling, 421
 Perforant path–dentate gyrus path-
 way, 237
 Phosphatidylcholine, 105
 Phosphatidylethanolamine, 105
 Phospholipids, 105
 Physical dependence, 551
 Physostigmine, 209
 Picrotoxin, 115
 Place aversion, 193
 Plus-maze, 123
 PMMA, 311
 PND, postnatal day, 23
 Porsolt forced swim test, 65
 Porsolt test, 15
 Postsynaptic, 439
 Potassium, 243
 Preclinical models, 551
 Prenatal, 23
 Prepulse inhibition, 219
 Presynaptic, 439
 Primary cell cultures, 157
 Prolactin, 209
 Psychomotor function, 427
 Psychostimulants, 65
 PTZ, 291
 Pyridostigmine, 209

 Quinpirole, 23, 181

 Radial arm maze, 133, 467
 Radiant heat test, 95
 Radioligand binding assays, 157
 Rat, 95, 123, 157, 175, 267, 279, 291,
 305, 317, 325, 359, 421, 505, 551
 Reaction time, 427
 Receptor binding, 43
 Reconstituted receptors, 457
 Reference memory, 133
 Reinforcement, 439
 Retention of tolerance, 367
 Reward, 439, 531
 Risperidone, 237
 Rotarod, 387

- Saccharin, 279
S-adenosyl-L-methionine, 105
Sarin, 175
sc, subcutaneous, 23
SCH23390, 181
Schizophrenia, 219, 561
Scopolamine, 427
Sedation, 427
Seizures, 421
Selected lines, 167
Selective breeding, 387
Self-administration, 257
Sensitization, 65
Sensorimotor, 95
Sensory deficit, 561
Serotonin, 123, 411, 531
Sex differences, 149, 397
SIB-1553A, 505
Side effect, 427
SKF81297, 181
SKF 82958, 23
SKF, SKF 82958 challenge drug at
 1.0 or 10 mg/kg, 23
Sleep time, 387
Sleep–wake cycle, 305
Sleep–wakefulness and temperature,
 115
Smoking, 439, 515, 561
Social interaction test, 491
Social isolation, 397
Sodium, 243
Somatic signs, 531
Spatial memory, 175
Sprague–Dawley rats, 475
Sprague–Dawley strain, 397
Startle, 219
State dependency, 133
Stereotyped movements, 367
Stereotypy, 397
Steroid hormones, 243
Stimulants, 311
Strain, 219
Strain differences, 411
Streptozotocin, 325
Stress, 1, 77
Striatum, 55, 497
Substance abuse, 23
Synaptic plasticity, 439
Tail suspension test, 187
Temporal cortex, 571
Thiamine deficiency, 227
Tobacco, 439
Tolerance, 439
Training dose, 381
TRH, 15
Two-lever choice, 257
Ultrasonic vocalization, 317
Ultrasonic vocalizations (USVs), 273
Unbaited radial-arm maze, 181
Unconditioned preparatory behavior,
 181
Unilateral lesion, 43
VEH, vehicle-treated, 23
Vertical activity, 475
Visual hallucinations, 571
Vomiting, 267
von Frey filaments, 95
Wheel running, 359
Whole-cell recordings, 457
Wistar rat, 227
Withdrawal, 65
Working memory, 133
X-maze, 411
Zonisamide, 375